Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | NQO2 | P16083 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104062 | 0.89 | KDM4E (0.36) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL10104060 | 0.87 | ESR1 (0.38) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL12657464 | 0.85 | ESR1 (0.41) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL16070533 | 0.85 | — | — | |
| SCHEMBL10104068 | 0.81 | KDM4A (0.38) | KDM4E | |
| SCHEMBL16070568 | 0.80 | — | — | |
| SCHEMBL19649302 | 0.79 | PTGS1 (0.34) | PTGS1PTGS2KDM4E | |
| SCHEMBL19649036 | 0.78 | KDM4E (0.30) | KDM4E | |
| SCHEMBL10104055 | 0.77 | KDM4E (0.32) | KDM4E | |
| SCHEMBL10104083 | 0.76 | CHRM2 (0.38) | ESR1ESR2PTGS1PTGS2NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004759-B1 | METHOD OF DYEING AND LIGHTENING KERATIN MATERIALS IN THE PRESENCE OF A REDUCING AGENT COMPRISING A FLUORESCENT DISULPHIDE DYE | ORÉAL L (FR) | 2016-05-11 | — | — | EP | disclosed |
| EP-2781556-A1 | Method of colouring and lightening keratin materials in the presence of a reducing agent comprising a fluorescent disulphide dye | L'Oréal (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-8097044-B2 | Hair compositions comprising at least one disulfide direct dye and at least one alkaline hydroxide agent and simultaneous hair shaping and dyeing processes | L'OREAL S.A. (FR) | 2012-01-17 | — | — | US | disclosed |
| US-8038731-B2 | hair dyes contains naphthylimide thiol or disulphide groups; resistant and visible lightening effect on dark keratin fibres; cosmetics | L'OREAL S.A. (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20090313769-A1 | METHOD OF DYEING AND LIGHTENING KERATIN MATERIALS IN THE PRESENCE OF A REDUCING AGENT COMPRISING A FLUORESCENT DISULPHIDE DYE | L'OREAL S.A. (FR) | 2009-12-24 | — | — | US | disclosed |
| US-20090126755-A1 | Hair compositions comprising at least one disulfide direct dye and at least one alkaline hydroxide agent and simultaneous hair shaping an dyeing processes | L'OREAL S.A. (FR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090126755-A1 | Hair compositions comprising at least one disulfide direct dye and at least one alkaline hydroxide agent and simultaneous hair shaping an dyeing processes | KRT18, DSG1, ALPG | ESR1 3948/4885ESR2 3056/4885PTGS1 2478/4885 |
| US-20090313769-A1 | METHOD OF DYEING AND LIGHTENING KERATIN MATERIALS IN THE PRESENCE OF A REDUCING AGENT COMPRISING A FLUORESCENT DISULPHIDE DYE | KRT18, DSG1, KRTCAP2 | ESR1 3454/4885ESR2 2442/4885PTGS1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.